Advertisement

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement

Dec

10

Today In Oncology

Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer

Abbreviated Azacitidine Regimen Improves Outcomes in Lower-Risk MDS

Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL

Chemotherapy-Free Regimen Improves Outcomes in Newly Diagnosed Patients With Ph-Positive ALL

Experimental CAR T-Cell Therapy Shows High Efficacy and a Favorable Safety Profile in Multiple Myeloma

Advertisement

© 2025 HSP News Service, L.L.C.